Current Price,D106N

The d106n formyl peptide interaction with cellular receptors is a crucial area of research in immunology and molecular biology. Specifically, the D106N mutation within certain peptide structures has been shown to significantly alter their binding affinity and specificity, particularly concerning formyl peptide receptors (FPRs). This mutation, where an aspartic acid residue at position 106 is replaced by asparagine, plays a vital role in understanding how these receptors recognize and respond to various formyl-containing molecules.

Formyl peptide receptors are a family of seven-transmembrane domain, G protein-coupled receptors (GPCRs) predominantly found on mammalian phagocytic cells like neutrophils and monocytes. Their primary function is to detect microbial molecules, particularly N-formyl peptides that are characteristic of bacterial proteins. This detection triggers a cascade of events, including chemotaxis, phagocytosis, and the release of inflammatory mediators, forming a critical part of the innate immune response.

Research into the structural basis of formyl peptide recognition has highlighted the importance of specific amino acid residues within the receptor's binding pocket. Studies have demonstrated that mutations, such as the D106N substitution, can dramatically impact ligand specificity. For instance, the D106N mutation has been observed to cause a similar change in ligand specificity as the R201A mutation. This alteration can lead to an enhanced ability to bind to specific peptides, even those not typically considered strong ligands for the wild-type receptor. A notable example is the enhanced binding to the HIV-1 peptide DP178 when this mutation is present. This suggests that the aspartic acid at position 106 normally plays a role in maintaining selectivity for certain formyl peptides.

Beyond bacterial detection, formyl peptide receptors have a broader range of functions. They are also involved in recognizing endogenous alarmins and play roles in inflammation and tissue repair. For example, the Formyl peptide receptor 2 (FPR2) is a receptor for formylated peptides and specific pro-resolving mediators, indicating its involvement in resolving inflammatory processes. The understanding of these diverse ligand interactions is continuously evolving.

The implications of these interactions extend to various physiological and pathological conditions. Research into targeting formyl peptide receptor 1 reduces brain inflammation and neurodegeneration highlights the therapeutic potential of modulating these receptor pathways. Understanding how mutations like D106N influence receptor-ligand interactions is therefore paramount for developing targeted therapies.

Furthermore, the formyl peptide system is implicated in conditions beyond the typical immune response. For example, the PrP(106-126) is chemotactic for human monocytes through a G protein-coupled receptor, suggesting a role for formylated peptide signaling in prion-related diseases or other neurological conditions involving protein aggregation. The ability of FPRs to recognize a diverse array of peptides, including those derived from viruses like HIV and Ebola, underscores their broad significance in host defense.

The study of N-formyl peptide receptors (FPRs) is a dynamic field. Ongoing research continues to explore the intricate mechanisms of ligand binding, receptor activation, and downstream signaling. The D106N mutation serves as a key example of how specific amino acid changes can profoundly influence the functional properties of these critical immune sensors, paving the way for a deeper understanding of host defense, inflammation, and potential therapeutic interventions. The exploration of formyl peptide binding and its modulation remains a significant area of scientific inquiry.